SML1855
AZD5438
≥97% (HPLC)
别名:
4-[2-Methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(methylsulfonyl)phenyl]-2-pyrimidinamine, AZD 5438, AZD-5438
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
Quality Level
assay
≥97% (HPLC)
form
powder
color
yellow to orange
solubility
DMSO: 20 mg/mL, clear
storage temp.
2-8°C
SMILES string
[S](=O)(=O)(C)c1ccc(cc1)Nc2nc(ccn2)c3[n](c(nc3)C)C(C)C
InChI
1S/C18H21N5O2S/c1-12(2)23-13(3)20-11-17(23)16-9-10-19-18(22-16)21-14-5-7-15(8-6-14)26(4,24)25/h5-12H,1-4H3,(H,19,21,22)
InChI key
WJRRGYBTGDJBFX-UHFFFAOYSA-N
Biochem/physiol Actions
AZD5438 is an orally active, potent and reversible inhibitor against cyclin-dependent kinases (IC50 = 6 nM/Cyc E-CDK2, 14 nM/p25-CDK5, 16 nM/Cyc B1-CDK1, 20 nM/Cyc T-CDK9, 21 nM/Cyc D3-CDK6, 45 nM/Cyc A-CDK2, 449 nM/Cyc D1-CDK4, 821 nM/Cyc H-CDK7; [ATP] = Km) and glycogen synthase kinase GSK-3β≤ (IC50 = 17 nM) without significant inhibitory potency toward 30 other kinases (≤75% inhibition at 10 μM). AZD5438 effectively inhibits cellular CDK substrates phosphorylation and displays antiproliferation activity against a broad spectrum of human cancer cultures (IC50 from 0.2 μM/MCF to 1.7 μM/ARH-77) by inducing cell cycle arrest at G2-M, S, and G1. Oral administration (50 mg/kg/12 h or 75 mg/kg/day) is efficacious against human tumor xenograft growth in mice in vivo.
AZD5438 is an orally active, potent and reversible inhibitor against cyclin-dependent kinases.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Nozomi Tomimatsu et al.
Nature communications, 5, 3561-3561 (2014-04-08)
Resection of DNA double-strand breaks (DSBs) is a pivotal step during which the choice between NHEJ and HR DNA repair pathways is made. Although CDKs are known to control initiation of resection, their role in regulating long-range resection remains elusive.
Kate F Byth et al.
Molecular cancer therapeutics, 8(7), 1856-1866 (2009-06-11)
Deregulation of the cell cycle has long been recognized as an essential driver of tumorigenesis, and agents that selectively target key cell cycle components continue to hold promise as potential therapeutics. We have developed AZD5438, a 4-(1-isopropyl-2-methylimidazol-5-yl)-2-(4-methylsulphonylanilino) pyrimidine, as a
Camille D A Terfve et al.
Nature communications, 6, 8033-8033 (2015-09-12)
Mass spectrometry is widely used to probe the proteome and its modifications in an untargeted manner, with unrivalled coverage. Applied to phosphoproteomics, it has tremendous potential to interrogate phospho-signalling and its therapeutic implications. However, this task is complicated by issues
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SML1855-5MG | 04061832452432 |
| SML1855-25MG | 04061832452425 |